About Ubrogepant free base trihydrate 54.9 mg equivalent to Ubrogepant 50 mg
            
            Class: | Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist  
Use: | Acute treatment of migraine in adults  
Adult dose: | 50 mg orally, may be taken as a single dose; if needed, a second dose of 50 mg may be taken after at least 2 hours, not to exceed 200 mg in a 24-hour period  
Pediatric dose: | Safety and efficacy not established in pediatric patients under 18 years  
Side effects: | Nausea, somnolence, dry mouth, fatigue, constipation  
Contraindications: | Hypersensitivity to ubrog
         
        
            
                
                
                    
                        Drug Class
                    
                    Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
                 
                
                
                    
                        Uses & Indications
                    
                    Acute treatment of migraine in adults
                 
                
                
                    
                        Storage Requirements
                    
                    Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: Allergan Sales LLC [New Jersey;United States of America], United States of America
                    
                    
                    Package Size
                    10's (1's Unit-Dose Packet x 10)
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 1734.00
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        50 mg orally, may be taken as a single dose; if needed, a second dose of 50 mg may be taken after at least 2 hours, not to exceed 200 mg in a 24-hour period
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy not established in pediatric patients under 18 years
                    
                 
                
                
                    
                        Side Effects
                    
                    Nausea, somnolence, dry mouth, fatigue, constipation
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypersensitivity to ubrogepant or any component of the formulation
         
        
        
            
                Important Warnings
            
            Risk of hypersensitivity reactions; not for the preventive treatment of migraine; use caution in patients with hepatic impairment
         
        
        
        
        
        
            
                Related Medicines in Same Category
            
            
                See also: Other Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist medicines available in UAE pharmacies
            
            
            
                Erenumab
            
            
            
                Erenumab
            
            
         
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.